

DESCRIPTION

Source Mouse myeloma cell line, NS0-derived
Arg45-Leu417 (Asp161Glu & Arg162Lys), with a C-terminal 10-His tag
Accession # P05981
Manufactured and tested under cGMP guidelines.

N-terminal Sequence Analysis Arg₄₅-Ser-Asp-Gln-Glu-Pro-Leu-Tyr-Pro-Val

Predicted Molecular Mass 42 kDa

SPECIFICATIONS

SDS-PAGE 40-43 kDa, reducing conditions

Activity Measured by its ability to cleave *tert*-butoxycarbonyl-Gln-Arg-Arg-7-amino-4-methylcoumarin (Boc-QRR-AMC). The specific activity is >20,000 pmol/min/μg, as measured under the described conditions. See Activity Assay Protocol on www.RnDSystems.com.

Endotoxin Level <1.0 EU per 1 μg of the protein by the LAL method.

Purity >95%, by SDS-PAGE with silver staining, under reducing conditions.

Formulation Supplied as a 0.2 μm filtered solution in Sodium Acetate and NaCl. See Certificate of Analysis for details.

Activity Assay Protocol

- Materials**
- Activation Buffer: 0.1 M Tris, 10 mM CaCl₂, 0.15 M NaCl, 0.05 % Brij-35, pH 8.0
 - Assay Buffer: 50 mM Tris, pH 9.0
 - Recombinant Human Hepsin (rhHepsin) (Catalog # 4776-SE)
 - Fluorogenic Peptide Substrate: BOC-Gln-Arg-Arg-AMC (Bachem, Catalog # I-1655), 5 mM stock in 50:50 DMSO:Methanol
 - F16 Black Maxisorp Plate (Nunc, Catalog # 475515)
 - Fluorescent Plate Reader (Model: SpectraMax Gemini EM by Molecular Devices) or equivalent

- Assay**
1. Dilute rhHepsin to 100 μg/mL in Activation Buffer.
 2. Incubate at 37 °C for 24 hours.
 3. Dilute activated rhHepsin to 0.2 ng/μL in Assay Buffer.
 4. Dilute Substrate to 200 μM in Assay Buffer.
 5. Load 50 μL of the 0.2 ng/μL rhHepsin in a black well plate and start the reaction by adding 50 μL of 200 μM Substrate. Include a Substrate Blank containing 50 μL Assay Buffer and 50 μL of 200 μM Substrate.
 6. Read at excitation and emission wavelengths of 380 nm and 460 nm (top read), respectively in kinetic mode for 5 minutes.
 7. Calculate specific activity:

$$\text{Specific Activity (pmol/min/}\mu\text{g)} = \frac{\text{Adjusted } V_{\text{max}}^* \text{ (RFU/min)} \times \text{Conversion Factor}^{**} \text{ (pmol/RFU)}}{\text{amount of enzyme (}\mu\text{g)}}$$

*Adjusted for Substrate Blank

**Derived using calibration standard 7-Amino, 4-Methyl Coumarin (AMC) (Sigma, Catalog # A-9891).


- Final Assay Conditions** Per Well:
- rhHepsin: 0.010 μg
 - Substrate: 100 μM

PREPARATION AND STORAGE

Shipping The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.

- Stability & Storage** Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months, -70 °C as supplied.
 - 3 months, -70 °C under sterile conditions after opening.

DATA



BACKGROUND

R&D Systems' GMP proteins are produced according to relevant sections of the following documents: WHO TRS, No. 822, 1992 Annex 1, Good Manufacturing Practices for Biological Products; USP Chapter 1043, Ancillary Materials for Cell, Gene and Tissue-Engineered Products and USP Chapter 92, Growth Factors and Cytokines Used in Cell Therapy Manufacturing.

R&D Systems' quality focus includes:

- Manufacturing and testing under an ISO 9001:2008 and ISO 13485:2003 certified quality system
- Documented processes and QA control of documentation and process changes
- Personnel training programs
- Raw material testing and vendor qualification/monitoring
- Fully validated equipment, processes and test methods
- Equipment calibration schedules using a computerized calibration program
- Facility maintenance, safety programs and pest control
- Material review process for variances
- Monitoring of stability over product shelf-life

R&D Systems strives to provide our customers with the analytical characteristics of each product so that customers may determine whether our products are appropriate for their research. The Certificate of Analysis provided contains the following lot specific information:

- N-terminal amino acid analysis, SDS-PAGE analysis, and endotoxin level (as determined by LAL assay) performed on each bulk QC lot, not on individual bottlings of each QC lot
- Post-bottling lot-specific bioassay results (compliance with an established range) and results of microbial bioburden testing (using broth culture, Sabourand's dextrose and blood agar plates with results reported at 3 days and at 7 days)

Additional testing and documentation requested by the customer can be arranged at an additional cost. Testing may include, but is not limited to, USP sterility testing, positive identity testing, testing for adventitious agents and testing for residual host cell content.

Production records and facilities are available for examination by appropriate personnel on-site at R&D Systems in Minneapolis, Minnesota USA.

R&D Systems sells its GMP grade recombinant protein products for research use or further manufacturing use in *ex vivo* cell therapy applications. They are not for *in vivo* use or for use as therapeutic or other drugs, biologic products or devices. Please read the following End User Terms prior to using this product.

PRODUCT SPECIFIC NOTICES

END USER TERMS OF USE OF PRODUCT

The following terms are offered to you upon your acceptance of these End User Terms of Use of Product. By using this product, you indicate your acknowledgment and agreement to these End User Terms of Use of Product. If you do not agree to be bound by and comply with all of the provisions of these End User Terms of Use of Product, you should contact your supplier of the product and make arrangements to return the product.

We suggest you print and retain a copy of these End User Terms of Use of Product for your records.

The End User is aware that R&D Systems, Inc. sells its GMP products for research use only or further manufacturing and not for *in vivo* use, the production of therapeutics or other drugs or for biologic products or devices. The End User further agrees, as a condition of the sale of R&D Systems' GMP products that: a) the End User will not use this GMP Product in any procedure wherein the product may be directly or indirectly administered to humans, unless the End User has obtained, or prior to their use will have obtained, an Investigational New Drug (IND) exemption from the FDA and will use the product only in accordance with the protocols of such IND and of the Institutional Review Board overseeing the proposed research, or b) the End User will use the products outside of the United States in accordance with the protocols of research approved by the Institutional Review Board or authorized ethics committee and regulatory agencies to which the End User is subject to in their territory.

R&D Systems, Inc. has the right, at its sole discretion, to modify, add or remove any terms or conditions of these End User Terms of Use without notice or liability to you. Any changes to these End User Terms of Use are effective immediately following the printing of such changes on this product insert. The most recent version of these End User Terms of Use of Product may be found at: RnDSystems.com/Legal.

You agree to review these End User Terms of Use of Product to ensure any subsequent use by you of R&D Systems' GMP Products following changes to these End User Terms of Use of Product constitutes your acceptance of all such changes.

TERMS AND CONDITIONS

The following limitation applies to R&D Systems' warranty and liability for damages: All products are warranted to meet R&D Systems' published specifications when used under normal laboratory conditions.

R&D SYSTEMS DOES NOT MAKE ANY OTHER WARRANTY OR REPRESENTATION WHATSOEVER, WHETHER EXPRESS OR IMPLIED, WITH RESPECT TO ITS PRODUCTS. IN PARTICULAR, R&D SYSTEMS DOES NOT MAKE ANY WARRANTY OF SUITABILITY, NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE.

NOTWITHSTANDING ANY OTHER PROVISIONS OF THESE TERMS AND/OR ANY OTHER AGREEMENT BETWEEN R&D SYSTEMS AND PURCHASER FOR THE PURCHASE OF THE PRODUCTS, R&D SYSTEMS' TOTAL LIABILITY TO PURCHASER ARISING FROM OR IN RELATION TO THESE TERMS, AN AGREEMENT BETWEEN THE PARTIES OR THE PRODUCTS, WHETHER ARISING IN CONTRACT, TORT OR OTHERWISE SHALL BE LIMITED TO THE TOTAL AMOUNT PAID BY PURCHASER TO R&D SYSTEMS FOR THE APPLICABLE PRODUCTS. IN NO EVENT WILL R&D SYSTEMS BE LIABLE FOR THE COST OF PROCUREMENT OF SUBSTITUTE GOODS.

Full details of R&D Systems' Terms and Conditions of Sale can be found online at: RnDSystems.com/Legal.